We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 08, 2020

Durable Ibrutinib Responses in Relapsed/Refractory Marginal Zone Lymphoma

Blood advances

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood advances
Durable Ibrutinib Responses in Relapsed/Refractory Marginal Zone Lymphoma: Long-Term Follow-Up and Biomarker Analysis
Blood Adv 2020 Nov 24;4(22)5773-5784, A Noy, S de Vos, M Coleman, P Martin, CR Flowers, C Thieblemont, F Morschhauser, GP Collins, S Ma, S Peles, SD Smith, JC Barrientos, E Chong, S Wu, LW Cheung, K Kwei, B Hauns, I Arango-Hisijara, R Chen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading